{"name":"Immutep S.A.S.","slug":"immutep-sas","ticker":"","exchange":"","domain":"immutepsas.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"cisplatin or carboplatin + pemetrexed","genericName":"cisplatin or carboplatin + pemetrexed","slug":"cisplatin-or-carboplatin-pemetrexed","indication":"Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy)","status":"phase_3"}]}],"pipeline":[{"name":"cisplatin or carboplatin + pemetrexed","genericName":"cisplatin or carboplatin + pemetrexed","slug":"cisplatin-or-carboplatin-pemetrexed","phase":"phase_3","mechanism":"This combination uses platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed, a folate antagonist that inhibits multiple enzymes in nucleotide synthesis, to damage cancer cell DNA and disrupt cell division.","indications":["Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}